{"filing":{"accession_number":"0001434647-26-000067","cik":"0001434647","ticker":"ZVRA","company_name":"ZEVRA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"zvra-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805.htm"},"events":[{"id":24848,"run_id":22525,"accession_number":"0001434647-26-000067","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Zevra's Q2 2026 financial results, including net revenue of $39.7 million (53% increase YoY), net income of $8.8 million, and cash position of $260.2 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, product performance metrics for MIPLYFFA, and pipeline updates.","company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25538,"accession_number":"0001434647-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Zevra's Q2 2026 financial results, including net revenue of $39.7 million (53% increase YoY), net income of $8.8 million, and cash position of $260.2 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, product performance metrics for MIPLYFFA, and pipeline updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:26:49.583253+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25538,"accession_number":"0001434647-26-000067","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Zevra's Q2 2026 financial results, including net revenue of $39.7 million (53% increase YoY), net income of $8.8 million, and cash position of $260.2 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial highlights, product performance metrics for MIPLYFFA, and pipeline updates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:26:49.583253+00:00","company_name":"ZEVRA THERAPEUTICS, INC.","ticker":"ZVRA","filing_date":"2026-08-05"}]}